Alphatec Holdings (ATEC) opened 2026 with Q1 revenue of US$192.1 million and a basic EPS loss of US$0.22, alongside a net loss of US$33.9 million, putting fresh numbers around a story that investors have been watching closely. Over the past year, the company has seen quarterly revenue move from US$169.2 million in Q1 2025 to a recent peak of US$212.9 million in Q4 2025, before landing at US$192.1 million in Q1 2026. EPS has ranged from a loss of US$0.35 to a loss of US$0.14 in that period, keeping the focus squarely on how quickly margins can tighten and losses can be contained.

See our full analysis for Alphatec Holdings.

With the headline numbers on the table, the next step is to see how this earnings print lines up against the bigger stories around Alphatec Holdings, highlighting where the data supports the current narratives and where it pushes back.

Losses On Trailing Basis Remain Heavy At US$125 Million

• Over the last twelve months, Alphatec reported total revenue of US$787.1 million and a net loss of US$125.4 million, compared with a Q1 2026 quarterly net loss of US$33.9 million on revenue of US$192.1 million.
• Consensus narrative expects rising surgeon adoption and new technologies to support revenue growth, yet the trailing loss shows that profitability is still a work in progress.
  • Analysts in that balanced view are looking for revenue to grow about 17.4% a year and for profit margins to move from a negative level to 8.5% over roughly three years. At the same time, trailing losses of US$125.4 million and a trailing EPS loss of US$0.83 underline how far reported results are from those targets today.
  • The same narrative points to earnings of about US$93.9 million in a future year. This stands in clear contrast to the latest four quarter run rate where losses have averaged more than US$30 million per quarter, so anyone leaning on that outlook has to be comfortable with a significant gap between current and expected profitability.

Low 1.4x P/S Versus Peers But Still Loss Making

• The stock trades on a P/S of 1.4x versus 2.7x for the wider US Medical Equipment group and 4.1x for peers, while trailing twelve month EPS remains a loss of US$0.83 and net losses have widened over about five years at roughly 4.8% a year.
• Bulls argue that this combination of lower P/S and projected earnings growth of 54.6% a year points to mispricing, but the current loss profile gives bears concrete numbers to point to.
  • The bullish side leans on that 54.6% projected earnings growth and 13.1% projected annual revenue growth as justification for a higher analyst price target of US$18.00 than the current share price of US$7.75. In contrast, the actual trailing net loss of US$125.4 million and ongoing quarterly losses mean the business has not yet reached the profitability that would underpin those expectations.
  • Bears highlight that losses have grown about 4.8% a year over five years and that recent insider selling and share price volatility strengthen the case for caution, even though the current 1.4x P/S multiple and the gap to analyst expectations show that the market is already pricing in some of those concerns.

Stay curious about how Alphatec's growth story squares with its current losses and why some investors still see room for optimism. 🐂 Alphatec Holdings Bull Case

DCF Fair Value Of US$26.32 Versus US$7.75 Price

• A cited DCF fair value of US$26.32 per share compared with the current share price of US$7.75 highlights a large valuation gap alongside a trailing twelve month net loss of US$125.4 million and all recent quarters in the red.
• Critics highlight that relying on that DCF gap while the company is still unprofitable is risky, and recent insider selling plus share volatility give extra support to the cautious narrative.
  • The bearish view notes that net losses have increased about 4.8% a year over five years and that the business remains loss making across the latest six reported quarters, so the DCF fair value sits against a backdrop of persistent red ink rather than a clear track record of earnings improvement.
  • Those same skeptics also point to recent share price volatility and insider selling in the last three months as signals that management and the market are still adjusting to this loss profile, which can weigh on confidence even when models indicate a much higher fair value than US$7.75.

If you are weighing these risks against the upside implied by forecasts and modelled value, it helps to see how the cautious case is built from the same numbers. 🐻 Alphatec Holdings Bear Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Alphatec Holdings on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Mixed on the story so far or leaning one way already? This is a good moment to move quickly, review the numbers yourself and weigh up the 3 key rewards and 2 important warning signs.

See What Else Is Out There

Alphatec is still carrying heavy trailing losses of US$125.4 million, ongoing quarterly losses and a 1.4x P/S that reflects real profitability concerns.

If that loss profile and volatility make you cautious, it is worth balancing your portfolio ideas with companies in the 74 resilient stocks with low risk scores that score better on stability and risk today.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.